Drug Profile
Zocaglusagene nuzaparvovec - Astellas
Alternative Names: AT 982; AT-002 - Astellas Gene Therapies; AT845Latest Information Update: 03 Mar 2023
Price :
$50
*
At a glance
- Originator Audentes Therapeutics
- Developer Astellas Gene Therapies
- Class Gene therapies
- Mechanism of Action Alpha glucosidase replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Glycogen storage disease type II
Most Recent Events
- 22 Feb 2023 Adverse events and efficacy data from a phase-I/II FORTIS trial in Glycogen storage disease type II released by Astellas Pharma
- 06 Feb 2023 Astellas Pharma plans to reinitiate the FORTIS phase I/II clinical trial of AT 845 in adults with late-onset Pompe disease (LOPD) in second quarter of 2023
- 19 Jan 2023 US FDA lifts clinical hold from the FORTIS phase I/II trial in Glycogen storage disease type II